Meningitis Therapy
Ertapenem active against resistant pneumococci
Published in TB and Outbreaks Week, July 22nd, 2003
According to published research from Switzerland, "the penetration of ertapenem, a new carbapenem with a long half-life, reached 7.1% and 2.4% into inflamed and noninflamed meninges, respectively."
"Ertapenem had excellent antibacterial activity in the treatment of experimental meningitis due to penicillin-sensitive and -resistant pneumococci, leading to a decrease of 0.69 ± 0.17 and 0.59 ± 0.22 log10 CFU/mL/h, respectively, in the viable cell counts in the cerebrospinal fluid," reported P. Cottagnoud and coauthors at Inselspital...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Infectious Disease Therapy
Daptomycin effective against resistant staphylococcal, enterococcal pathogens - Infectious Disease
Role of RovA protein in Yersinia enterocolitica infection elucidated - Infectious Disease
Transmission between aquatic birds promotes influenza virus reassortment - Tuberculosis Pathogenesis
Host coronin may not support mycobacterial growth in macrophages - Tuberculosis Pathogenesis
Interleukin-4 reduces toll-like receptor expression - AIDS Therapy
Data shows reduced opportunistic infections in AIDS patients treated with HE2000 - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
